<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00936780</url>
  </required_header>
  <id_info>
    <org_study_id>IC001: V1.1</org_study_id>
    <nct_id>NCT00936780</nct_id>
  </id_info>
  <brief_title>Infinnium-Core™ Registry for the Treatment of Patients With De Novo Coronary Lesions</brief_title>
  <official_title>Safety and Efficacy of the Infinnium-Core™ Paclitaxel-Eluting Coronary Stent System for the Treatment of Patients With De Novo Coronary Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahajanand Medical Technologies Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahajanand Medical Technologies Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of Infinnium-Core™ Registry is to assess the safety and efficacy of the&#xD;
      Infinnium-Core™ Paclitaxel Eluting Coronary Stent System in de novo Coronary Lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infinnium-Core™ Registry is a multi-centric, prospective study. Approximately 150 patients&#xD;
      will be enrolled in the study. Patients will be followed for two years post-procedure.&#xD;
&#xD;
      Data analysis will include all statistically pre assigned 20% patients and all patients who&#xD;
      have repeat angiography due to complication. The diabetic patients will be specified as a&#xD;
      high risk subset in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    market demand from paclitaxel to sirolimus drug-eluting stent&#xD;
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>30 days and 9 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ANGIOGRAPHIC</measure>
    <time_frame>12 months</time_frame>
    <description>In Angiographic outcome measures the Minimal lumen diameter (MLD), % diameter stenosis, In-Stent and In-segment late loss, Proximal late loss, Distal late loss and Binary restenosis rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Infinnium-Core™ Paclitaxel eluting Coronary Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Infinnium-Core™ Paclitaxel eluting Coronary Stent</intervention_name>
    <description>Infinnium-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Drug concentration is 1.36 µg/mm2.</description>
    <arm_group_label>Infinnium-Core™ Paclitaxel eluting Coronary Stent</arm_group_label>
    <other_name>Drug Eluting Stent (DES)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Eligible for percutaneous coronary intervention (PCI).&#xD;
&#xD;
          3. Acceptable candidate for CABG.&#xD;
&#xD;
          4. Clinical evidence of ischemic heart disease and/or a positive territorial functional&#xD;
             study. Documented stable angina pectoris ((Canadian Cardiovascular Society (CCS)&#xD;
             Classification 1,2,3 or 4) or unstable angina pectoris with documented ischemia&#xD;
             (Braunwald Class IB-C, IIB-C or IIIB-C), or documented silent ischemia.&#xD;
&#xD;
          5. The target lesion is a single de novo coronary artery lesion with ≥ 50% and &lt; 100%&#xD;
             stenosis in one of the major epicardial territories (LAD, LCX or RCA). A second target&#xD;
             lesion in another major epicardial vessel could be treated and this second lesion&#xD;
             should fit with the inclusion/exclusion criteria and will receive the same type of&#xD;
             stent.&#xD;
&#xD;
          6. The target lesion must be covered by one study stent, preferably with a margin of 3 mm&#xD;
             on each side of the lesion.&#xD;
&#xD;
          7. The target lesion must be ≤ 37 mm in length by visual estimate.&#xD;
&#xD;
          8. The target reference vessel diameter must be ≥ 2.5 mm and ≤ 3.5 mm.&#xD;
&#xD;
          9. Patient or patient's legal representative has been informed of the nature of the study&#xD;
             and agrees to its provisions and has provided written informed consent as notified /&#xD;
             approved by the Institutional Review Board/Ethics Committee of the clinical site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female of childbearing potential.&#xD;
&#xD;
          2. Documented left ventricular ejection fraction (LVEF) ≤ 25%.&#xD;
&#xD;
          3. Evidence of an acute Q-wave or non-Q-wave myocardial infarction within 72 hours&#xD;
             preceding the index procedure.&#xD;
&#xD;
          4. Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®, Ceruvin) or&#xD;
             ticlopidine (Ticlid®), heparin, paclitaxel, cobalt, chromium, contrast agent (that&#xD;
             cannot be adequately pre-medicated).&#xD;
&#xD;
          5. A platelet count &lt;100,000 cells/mm3 or &gt; 700,000 cells/mm3 or a WBC &lt; 3,000 cells/mm3.&#xD;
&#xD;
          6. Acute or chronic renal dysfunction (creatinine &gt; 2.0 mg/dl or &gt; 150 µmol/L).&#xD;
&#xD;
          7. Target vessel has evidence of thrombus.&#xD;
&#xD;
          8. Target vessel is excessively tortuous which makes it unsuitable for proper stent&#xD;
             delivery and deployment.&#xD;
&#xD;
          9. Previous bare metal stenting (less than 1 year) anywhere within the target vessel.&#xD;
&#xD;
         10. Previous drug-eluting stenting anywhere within any epicardial vessel&#xD;
&#xD;
         11. The target lesion requires treatment with a device other than PTCA prior to stent&#xD;
             placement (e.g., but not limited to, directional coronary atherectomy, excimer laser,&#xD;
             rotational atherectomy, etc.)&#xD;
&#xD;
         12. Significant (&gt; 50%) stenosis proximal or distal to the target lesion that might&#xD;
             require revascularization or impede run-off.&#xD;
&#xD;
         13. Heavily calcified lesion and/or calcified lesion which cannot be successfully&#xD;
             predilated.&#xD;
&#xD;
         14. Target lesion is located in or supplied by an arterial or venous bypass graft.&#xD;
&#xD;
         15. Ostial target lesion.&#xD;
&#xD;
         16. Patient is currently participating in an investigational drug or device study,&#xD;
             including its follow-up period.&#xD;
&#xD;
         17. Within 30 days prior to procedure, patient has undergone a previous coronary&#xD;
             interventional procedure of any kind.&#xD;
&#xD;
         18. Within 60 days post-procedure, patient requires planned interventional treatment of&#xD;
             any non-target vessel. Planned intervention of the target vessel after the index&#xD;
             procedure is not allowed.&#xD;
&#xD;
         19. CVA within previous 6 months.&#xD;
&#xD;
         20. Unprotected Left Main (LM) coronary artery disease (stenosis &gt; 50%).&#xD;
&#xD;
         21. In the investigator's opinion, patient has a co-morbid condition(s) that could limit&#xD;
             the patient's ability to participate in the study, compliance with follow-up&#xD;
             requirements or impact the scientific integrity of the study.&#xD;
&#xD;
         22. Planned surgery within 6 months after the index procedure.&#xD;
&#xD;
         23. Life expectancy less than 1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bankers Heart Institute</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390 015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baroda Heart Institute &amp; Research Center</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHL Apollo Hospitals,</name>
      <address>
        <city>Indore.</city>
        <state>Madhya Pradesh.</state>
        <zip>452008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHL Apollo Hospitals</name>
      <address>
        <city>Indore</city>
        <state>Madhya Pradesh</state>
        <zip>452008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Government Medical College &amp; Super Speciality Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arneja Heart Institute</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sri Ramakrishna Heart Foundation &amp; Research Centre</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamilnadu</state>
        <zip>641 044</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <last_update_submitted>August 22, 2012</last_update_submitted>
  <last_update_submitted_qc>August 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Restenosis</keyword>
  <keyword>Stent thrombosis</keyword>
  <keyword>Coronary stents</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Drug Eluting Stents (DES)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

